^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Selective serotonin reuptake inhibitor

    Related drugs:
    1d
    SMART Trial Comparing Commonly Prescribed and Over the Counter Medications for the Treatment of Insomnia in Adults (clinicaltrials.gov)
    P4, N=1200, Not yet recruiting, University of Pennsylvania
    New P4 trial
    2d
    Efficacy and Safety of Sertraline Combined With Lactobacillus Crispatus in Adolescents With Depression : A Multicenter Randomized Controlled Trial (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, First Affiliated Hospital of Chongqing Medical University
    New P2 trial
    5d
    A Study Utilizing Escitalopram in Glioma Patients (clinicaltrials.gov)
    P2, N=20, Recruiting, University of Nebraska | Trial completion date: Aug 2027 --> Jun 2029 | Trial primary completion date: Dec 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    9d
    Can Immediate Post-injury Fluoxetine Improve the Recovery Trajectories of Victims in Bodily Trauma? (clinicaltrials.gov)
    P4, N=200, Recruiting, University of Florida | Trial completion date: Nov 2027 --> Mar 2027 | Trial primary completion date: Nov 2027 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    fluoxetine
    12d
    Targeting G3BP1-Mediated Stress Granules to Suppress SARS-CoV-2 Replication. (PubMed, ACS Infect Dis)
    In cell-based assays, two compounds─dexlansoprazole and citalopram─disrupted the G3BP1-N interaction with minimal cytotoxicity. Both compounds showed antiviral activity in human lung epithelial cells infected with either the WA strain or an Omicron (BA.1) strain of SARS-CoV-2. This work establishes a strategy to modulate SGs by targeting a host-virus PPI, highlighting G3BP1 as a potential therapeutic node for antiviral intervention.
    Journal
    |
    G3BP1 (G3BP Stress Granule Assembly Factor 1)
    13d
    MAG-DEP: Magnesium Supplementation With Fluoxetine for Cognitive Function in Depression (clinicaltrials.gov)
    P=N/A, N=40, Completed, Hasanuddin University
    New trial
    |
    fluoxetine
    14d
    Pupillometry in Delayed Sleep Wake Phase Disorder (clinicaltrials.gov)
    P=N/A, N=220, Recruiting, Northwestern University | Not yet recruiting --> Recruiting
    Enrollment open
    20d
    A Clinical Trial to Evaluate the Effect of Food on the Pharmacokinetics of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subjects (clinicaltrials.gov)
    P1, N=18, Completed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    New P1 trial
    20d
    NAP: National Adaptive Trial for PTSD Related Insomnia (clinicaltrials.gov)
    P3, N=673, Completed, VA Office of Research and Development | Active, not recruiting --> Completed
    Trial completion
    20d
    Food-effect Study of Ammoxetine Hydrochloride Enteric-coated Tablets (clinicaltrials.gov)
    P1, N=14, Completed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    New P1 trial
    21d
    PSY-PGx: Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders (clinicaltrials.gov)
    P=N/A, N=1470, Recruiting, Maastricht University Medical Center | Not yet recruiting --> Recruiting | N=820 --> 1470
    Enrollment open • Enrollment change
    23d
    Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV (clinicaltrials.gov)
    P2, N=186, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting --> Recruiting
    Enrollment open